Company profile
Annovis Bio, Inc.
NYSE: ANVS · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
33DFH 32DQ 32GM —SS 38
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$28.9M
Employees
7
as of 2026-08-20
Market cap
$78.7M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$28.9M-$28.9M2025
Operating income-$29.7M-$29.7M2025
Total assets$21.1M$21.1M2025
Liabilities$4.2M$4.2M2025
Equity$16.9M$16.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Annovis Bio, Inc.’s revenue?
Annovis Bio, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
HST Global, Inc.——MAIA Biotechnology, Inc.34DvTv Therapeutics Inc.57CPliant Therapeutics, Inc.48DXBiotech Inc.47DEloxx Pharmaceuticals, Inc.29DNeighbors
Chester →Key facts
CEOMaria L. Maccecchini
SectorHealthcare
IndustryBiotechnology
HeadquartersMalvern, PA
ExchangeNYSE: ANVS
Employees7
IPO date2020-01-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.